Abstract
HER2 is a transmembrane tyrosine kinase receptor in the EGFR (epidermal growth factor receptor) family. The role of HER2 has been most thoroughly studied in breast cancer, in which constitutively active HER2 is overexpressed in 18-22% of cases and is correlated with a poor prognosis. Hence, effective inhibition of the constitutive HER2 signaling in cancer cells has been a major goal in the design of therapies. Therapeutic targeting of HER2 with humanized antibodies such as trastuzumab (Herceptin TM, Genentech) South San Francisco, CA) has proven to be an effective approach for the treatment of breast cancer cells that over-express HER2. The encouraging results of trastuzumab in patients with metastatic and early breast cancer diseases have prompted the evaluation of new HER2 inhibitors for increasing the potential for combinatorial therapies. This review will focus on patents that target HER2 in anti-cancer treatment.
Keywords: HER2, breast cancer, target-therapies
Recent Patents on Anti-Cancer Drug Discovery
Title: Anti-HER2 Treatment and Breast Cancer: State of the Art, Recent Patents, and New Strategies
Volume: 4 Issue: 1
Author(s): Lorenzo Daniele and Anna Sapino
Affiliation:
Keywords: HER2, breast cancer, target-therapies
Abstract: HER2 is a transmembrane tyrosine kinase receptor in the EGFR (epidermal growth factor receptor) family. The role of HER2 has been most thoroughly studied in breast cancer, in which constitutively active HER2 is overexpressed in 18-22% of cases and is correlated with a poor prognosis. Hence, effective inhibition of the constitutive HER2 signaling in cancer cells has been a major goal in the design of therapies. Therapeutic targeting of HER2 with humanized antibodies such as trastuzumab (Herceptin TM, Genentech) South San Francisco, CA) has proven to be an effective approach for the treatment of breast cancer cells that over-express HER2. The encouraging results of trastuzumab in patients with metastatic and early breast cancer diseases have prompted the evaluation of new HER2 inhibitors for increasing the potential for combinatorial therapies. This review will focus on patents that target HER2 in anti-cancer treatment.
Export Options
About this article
Cite this article as:
Daniele Lorenzo and Sapino Anna, Anti-HER2 Treatment and Breast Cancer: State of the Art, Recent Patents, and New Strategies, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (1) . https://dx.doi.org/10.2174/157489209787002489
DOI https://dx.doi.org/10.2174/157489209787002489 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bioactive Sterol Derivatives Isolated from the <i>Pleurotus djamor</i> var. Roseus Induced Apoptosis in Cancer Cell Lines
Cardiovascular & Hematological Agents in Medicinal Chemistry Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry DNA Methylation and Breast Cancer
Current Genomics Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Meet Our Editorial Board Member
Current Cancer Drug Targets Anticancer Agents: VTA or VDA
Current Bioactive Compounds Cancer Stem Cells Stemness Transcription Factors Expression Correlates with Breast Cancer Disease Stage
Current Stem Cell Research & Therapy Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry Overview
Anti-Cancer Agents in Medicinal Chemistry Targeting Intestinal Transporters for Optimizing Oral Drug Absorption
Current Drug Metabolism Small Molecule Integrin Antagonists in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Targeting Nanoparticles as Drug Delivery Systems for Cancer Treatment
Current Nanoscience Sirtuins: Multifaceted Drug Targets
Current Molecular Medicine Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics
Current Pharmaceutical Biotechnology Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Role of Diabetes Mellitus in Diseases of the Gallbladder and Biliary Tract
Current Diabetes Reviews